| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SANA | Common Stock | Other | -2.83M | -24.7% | 8.62M | Sep 13, 2023 | By Flagship VentureLabs V, LLC | F1, F2 | ||
| transaction | SANA | Common Stock | Other | -4.93M | -37.94% | 8.06M | Sep 13, 2023 | By Flagship Ventures Fund V, L.P. | F3, F4 | ||
| transaction | SANA | Common Stock | Other | -345K | -25% | 1.04M | Sep 13, 2023 | By Flagship V VentureLabs Rx Fund, L.P. | F3, F5 | ||
| transaction | SANA | Common Stock | Other | -1.18M | -100% | 0 | Sep 13, 2023 | By Flagship Ventures Fund V General Partner LLC | F3, F6 | ||
| transaction | SANA | Common Stock | Other | -2.43M | -25% | 7.29M | Sep 13, 2023 | By Flagship Pioneering Fund VI, L.P. | F7, F8 | ||
| transaction | SANA | Common Stock | Other | -70.8K | -100% | 0 | Sep 13, 2023 | By Flagship Pioneering Fund VI General Partner LLC | F7, F9 | ||
| holding | SANA | Common Stock | 582K | Sep 13, 2023 | See footnote | F10 |
| Id | Content |
|---|---|
| F1 | On September 13, 2023, Flagship VentureLabs V LLC ("VentureLabs V") distributed in-kind to its members, pro rata and without consideration, 2,825,989 shares of the Issuer's common stock. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. |
| F2 | Represents shares held directly by VentureLabs V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F3 | On September 13, 2023, Flagship Ventures Fund V, L.P. ("Flagship Fund V") and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") distributed in-kind to their respective limited partners and sole general partner, Flagship Ventures Fund V General Partner, LLC ("Flagship Fund V GP"), pro rata and without consideration, 4,926,378 shares and 345,069 shares, respectively, of the Issuer's common stock. Flagship Fund V GP, in turn, distributed in-kind to its members, pro rata and without consideration, the aggregate of 1,181,745 shares it received from Flagship Fund V and Flagship Fund V Rx. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. |
| F4 | Represents shares held directly by Flagship Fund V. Includes 2,240,555 shares received in the distribution-in-kind from VentureLabs V described in footnote (1) above. Flagship V GP is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F5 | Represents shares held directly by Flagship Fund V Rx. Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F6 | Represents shares held directly by Flagship Fund V GP. Each of the reporting persons except Flagship Fund V GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F7 | On September 13, 2023, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed in-kind to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 2,431,281 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed in-kind to its members, pro rata and without consideration, the 70,813 shares it received from Flagship Fund VI. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. |
| F8 | Represents shares held directly by Flagship Fund VI. Flagship Fund VI GP is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F9 | Represents shares held directly by Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F10 | Consists of (i) 21,641 shares held directly by Dr. Afeyan, (ii) 20,606 shares held through a trust for the benefit of Dr. Afeyan's children (the "Trust") and (iii) 539,448 shares held by VENBA Holdings LLC ("VENBA"), an estate planning entity of which Dr. Afeyan is the sole manager. Represents an aggregate of 581,695 shares received in the distributions-in-kind described in footnotes (1), (3) and (7) above. Dr. Afeyan disclaims beneficial ownership of the shares held by the Trust and VENBA except to the extent of his pecuniary interest therein, if any. |